Difference between revisions of "Stub"
| Line 113: | Line 113: | ||
====Radiotherapy==== | ====Radiotherapy==== | ||
*Concurrent [[External_beam_radiotherapy|thoracic radiation therapy]] | *Concurrent [[External_beam_radiotherapy|thoracic radiation therapy]] | ||
| + | |||
| + | ==FEC & HP== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | FEC & HP: '''<u>F</u>'''luorouracil, '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''erceptin (Trastuzumab), '''<u>P</u>'''ertuzumab | ||
| + | ===Regimen=== | ||
| + | ====Chemotherapy==== | ||
| + | *[[Fluorouracil (5-FU)]] | ||
| + | *[[Epirubicin (Ellence)]] | ||
| + | *[[Cyclophosphamide (Cytoxan)]] | ||
| + | ====Targeted therapy==== | ||
| + | *[[Trastuzumab (Herceptin)]] | ||
| + | *[[Pertuzumab (Perjeta)]] | ||
==FULV & Trimetrexate== | ==FULV & Trimetrexate== | ||
Revision as of 00:07, 20 August 2020
Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon unless new evidence comes forward. This page is primarily to drive the Ontology.
Abiraterone & Enzalutamide
| back to top |
Regimen
Hormonotherapy
Bortezomib & Bevacizumab
| back to top |
Regimen
Targeted therapy
Bortezomib & Siltuximab
| back to top |
Regimen
Targeted therapy
Carboplatin & Epirubicin
| back to top |
Regimen
Chemotherapy
Carboplatin & Topotecan
| back to top |
Regimen
Chemotherapy
CE & Ipilimumab
| back to top |
CE & Ipilimumab: Carboplatin, Etoposide, Ipilimumab
Regimen
Chemotherapy
Immunotherapy
CE & Thalidomide
| back to top |
CE & Thalidomide: Carboplatin, Etoposide, Thalidomide
Regimen
Chemotherapy
Targeted therapy
Encorafenib monotherapy
| back to top |
Regimen
Targeted therapy
EP & Ipilimumab
| back to top |
EP & Ipilimumab: Etoposide, Platinol (Cisplatin), Ipilimumab
Regimen
Chemotherapy
Immunotherapy
EP, Tamoxifen, RT
| back to top |
EP, GM-CSF, RT: Etoposide, Platinol (Cisplatin), Tamoxifen, Radiation Therapy
Regimen
Chemotherapy
Hormonotherapy
Radiotherapy
- Concurrent thoracic radiation therapy
FEC & HP
| back to top |
FEC & HP: Fluorouracil, Epirubicin, Cyclophosphamide, Herceptin (Trastuzumab), Pertuzumab
Regimen
Chemotherapy
Targeted therapy
FULV & Trimetrexate
| back to top |
FULV & Trimetrexate: 5-FU & LeucoVorin (Folinic acid), Trimetrexate
Regimen
Chemotherapy
Ixabepilone & Bevacizumab
| back to top |
Regimen
Chemotherapy
Targeted therapy
MFL
| back to top |
MFL: Methyl-lomustine (MeCCNU), 5-FU & LeucoVorin (Folinic acid)
Regimen
Chemotherapy
Mitoxantrone & Hydrocortisone
| back to top |
Regimen
Chemotherapy
Hormonotherapy
PD & Pembrolizumab
| back to top |
PD & Pembrolizumab: Pomalidomide, Dexamethasone, Pembrolizumab
Regimen
Targeted therapy
Immunotherapy
Pixantrone & Rituximab
| back to top |
Regimen
Chemotherapy
Targeted therapy
TEC
| back to top |
TEC: Taxol (Paclitaxel), Epirubicin, Carboplatin
Regimen
Chemotherapy
TG+Bev
| back to top |
TG+Bev: Taxotere (Docetaxel), Gemcitabine, Bevacizumab
Regimen
Chemotherapy
Targeted therapy
TX+Bev
| back to top |
TX+Bev: Taxotere (Docetaxel), Xeloda (Capecitabine), Bevacizumab
Regimen
Chemotherapy
Targeted therapy
Vinorelbine & Hydrocortisone
| back to top |